These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36378297)

  • 1. Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate.
    Takahashi Y; Narita S; Shiota M; Miura M; Kagaya H; Kashima S; Yamamoto R; Nara T; Huang M; Numakura K; Saito M; Eto M; Habuchi T
    Eur J Clin Pharmacol; 2023 Jan; 79(1):89-98. PubMed ID: 36378297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer.
    Arasaratnam M; Crumbaker M; Bhatnagar A; McKay MJ; Molloy MP; Gurney H
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):139-146. PubMed ID: 31081533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II Trial of Abiraterone With Dutasteride for Second-Generation Antiandrogen- and Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer.
    Shiota M; Inoue R; Tashiro K; Kobayashi K; Horiyama S; Kanji H; Eto M; Egawa S; Haginaka J; Matsuyama H
    J Clin Pharmacol; 2023 Apr; 63(4):445-454. PubMed ID: 36484758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.
    Carton E; Noe G; Huillard O; Golmard L; Giroux J; Cessot A; Saidu NE; Peyromaure M; Zerbib M; Narjoz C; Guibourdenche J; Thomas A; Vidal M; Goldwasser F; Blanchet B; Alexandre J
    Eur J Cancer; 2017 Feb; 72():54-61. PubMed ID: 28027516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.
    Shiota M; Akamatsu S; Narita S; Sumiyoshi T; Fujiwara M; Uchiumi T; Ogawa O; Habuchi T; Eto M
    Pharmacogenomics J; 2021 Aug; 21(4):440-445. PubMed ID: 33649516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients.
    Blanchet B; Carton E; Alyamani M; Golmard L; Huillard O; Thomas-Scheomann A; Vidal M; Goldwasser F; Sharifi N; Alexandre J
    Pharmacol Res; 2018 Oct; 136():56-61. PubMed ID: 30142421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
    Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
    Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of dried blood spots as an alternative matrix for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in prostate cancer patients.
    Dillenburg Weiss TL; Gössling G; Venzon Antunes M; Schwartsmann G; Linden R; Gasparin Verza S
    J Pharm Biomed Anal; 2021 Feb; 195():113861. PubMed ID: 33373824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry.
    Bhatnagar A; McKay MJ; Crumbaker M; Ahire K; Karuso P; Gurney H; Molloy MP
    J Pharm Biomed Anal; 2018 May; 154():66-74. PubMed ID: 29533860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial.
    Alexandre J; Oudard S; Golmard L; Campedel L; Mseddi M; Ladoire S; Khalil A; Maillet D; Tournigand C; Pasquiers B; Goirand F; Berthier J; Guitton J; Dariane C; Joly F; Xylinas E; Golmard JL; Abdoul H; Puszkiel A; Decleves X; Carton E; Thomas A; Vidal M; Huillard O; Blanchet B
    Clin Pharmacokinet; 2024 Jul; 63(7):1025-1036. PubMed ID: 38963459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
    Lu C; Terbuch A; Dolling D; Yu J; Wang H; Chen Y; Fountain J; Bertan C; Sharp A; Carreira S; Isaacs WB; Antonarakis ES; De Bono JS; Luo J
    Ann Oncol; 2020 Sep; 31(9):1178-1185. PubMed ID: 32387417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
    Fizazi K; Chi KN; de Bono JS; Gomella LG; Miller K; Rathkopf DE; Ryan CJ; Scher HI; Shore ND; De Porre P; Londhe A; McGowan T; Pelhivanov N; Charnas R; Todd MB; Montgomery B
    Eur Urol; 2016 Sep; 70(3):438-44. PubMed ID: 26965562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5α-abiraterone, and their inactive glucuronide derivatives.
    Caron P; Turcotte V; Lévesque E; Guillemette C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1104():249-255. PubMed ID: 30537624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer.
    van Nuland M; Groenland SL; Bergman AM; Steeghs N; Rosing H; Venekamp N; Huitema ADR; Beijnen JH
    Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):244-251. PubMed ID: 31611636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
    Stein CA; Levin R; Given R; Higano CS; Nemeth P; Bosch B; Chapas-Reed J; Dreicer R
    Urol Oncol; 2018 Feb; 36(2):81.e9-81.e16. PubMed ID: 29150328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer.
    Myint ZW; Kolesar JM; McCorkle JR; Wu J; Ellis CS; Otto DE; Wang P
    Med Sci Monit; 2022 Oct; 28():e938091. PubMed ID: 36229939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
    Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
    Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
    Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E
    Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.